Discrepancies between a new highly sensitive Toxoplasma gondii ELISA assay and other reagents: interest of Toxo IgG Western blot

  • F. Leslé
  • F. Touafek
  • A. Fekkar
  • D. Mazier
  • L. ParisEmail author


Immunodiagnostic assays are commonly used to screen for maternal toxoplasmic seroconversion during pregnancy. The introduction to the market of a new highly sensitive IgG assay, the Elecsys Toxo IgG test, has resulted in discrepancy issues with other immunoassays because of a lack of standardisation. Western blot appears to be a good alternative gold standard to the dye test, as the latter is not routinely available. For the present prospective study, we compared the analytical performances of two immunoassays, Elecsys Toxo IgG (Roche Diagnostics) and Platelia Toxo IgG (Bio-Rad, Marnes la Coquette, France), to Toxo II IgG Western blot (LDBio, Lyon, France) using 231 consecutive sera with low or equivocal IgG titres. Of these 231 sera, 213 presented discrepancies, which showed the importance of a confirmation test. Of the Elecsys Toxo IgG-positive results, 100% were confirmed by the Western blot with a positive threshold of 30 IU/ml for Elecsys; in the equivocal area (1–30 IU/ml), Western blot is negative in 54% of cases. Our results suggest that the lower diagnostic cut-off of Platelia Toxo IgG should be further reduced. Our study indirectly confirms that monitoring, especially for pregnant women, must be done in the same laboratory using the same technique. The ability to diagnose very early seroconversion using Western blot merits further study.


Negative Predictive Value Toxoplasmosis Congenital Toxoplasmosis Toxoplasmic Infection Positive Threshold 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Baril L, Ancelle T, Goulet V et al (1999) Risk factors for Toxoplasma infection in pregnancy: a case–control study in France. Scand J Infect Dis 31(3):305–309PubMedCrossRefGoogle Scholar
  2. 2.
    Berger F, Goulet V, Le Strat Y et al (2009) Toxoplasmosis among pregnant women in France: risk factors and change of prevalence between 1995 and 2003. Rev Épidémiol Santé Publique 57(4):241–248PubMedCrossRefGoogle Scholar
  3. 3.
    Villena I (2008) Rapport d’activité 2008 du CNR toxoplasmose: Institut de Veille Sanitaire, 2008Google Scholar
  4. 4.
    Gilbert RE (ed) (1999) Epidemiology of infection in pregnant women. Springer-Verlag, Paris, FranceGoogle Scholar
  5. 5.
    Wallon M, Kodjikian L, Binquet C et al (2004) Long-term ocular prognosis in 327 children with congenital toxoplasmosis. Pediatrics 113(6):1567–1572PubMedCrossRefGoogle Scholar
  6. 6.
    Guerina NG, Hsu HW, Meissner HC et al (1994) Neonatal serologic screening and early treatment for congenital Toxoplasma gondii infection. The New England Regional Toxoplasma Working Group. N Engl J Med 330(26):1858–1863PubMedCrossRefGoogle Scholar
  7. 7.
    Lebech M, Andersen O, Christensen NC et al (1999) Feasibility of neonatal screening for toxoplasma infection in the absence of prenatal treatment. Danish Congenital Toxoplasmosis Study Group. Lancet 353(9167):1834–1837PubMedCrossRefGoogle Scholar
  8. 8.
    Petithory JC, Ambroise-Thomas P, De Loye J et al (1996) Serodiagnosis of toxoplasmosis: a comparative multicenter study of a standard scale through various actual tests and expression of the results in international units. Groupe de travail toxoplasmose du Contrôle national de qualité en parasotologie. Syndicat des fabricants de réactifs de laboratoire. Groupe de travail standardisation des tests sérologiques du Réseau européen de lutte contre la toxoplasmose congénitale. Bull World Health Organ 74(3):291–298PubMedGoogle Scholar
  9. 9.
    Köhler S, Rössler D, Hornauer S, Upmeier B, Franck J, Liesenfeld O (2010) Neutralization assay to resolve discrepancies between positive results in new highly sensitive anti-Toxoplasma gondii IgG assays and negative results in reference tests. Eur J Clin Microbiol Infect Dis 29(3):359–363PubMedCrossRefGoogle Scholar
  10. 10.
    Franck J, Garin YJ, Dumon H (2008) LDBio-Toxo II immunoglobulin G Western blot confirmatory test for anti-toxoplasma antibody detection. J Clin Microbiol 46(7):2334–2338PubMedCrossRefGoogle Scholar
  11. 11.
    Sabin AB, Feldman HA (1948) Dyes as microchemical indicators of a new immunity phenomenon affecting a protozoon parasite (Toxoplasma). Science 108(2815):660–663PubMedCrossRefGoogle Scholar
  12. 12.
    Reiter-Owona I, Petersen E, Joynson D et al (1999) The past and present role of the Sabin–Feldman dye test in the serodiagnosis of toxoplasmosis. Bull World Health Organ 77(11):929–935PubMedGoogle Scholar
  13. 13.
    Prusa AR, Hayde M, Unterasinger L et al (2010) Evaluation of the Roche Elecsys Toxo IgG and IgM electrochemiluminescence immunoassay for the detection of gestational Toxoplasma infection. Diagn Microbiol Infect Dis 68(4):352–357PubMedCrossRefGoogle Scholar
  14. 14.
    Jost C, Touafek F, Courtin R et al (2010) Early diagnosis of toxoplasmosis seroconversion: value of Western blot. In: Proceedings of the IVth International Congress on Congenital Toxoplasmosis (ICOCT 2010), Marseille, France, October 2010Google Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • F. Leslé
    • 1
  • F. Touafek
    • 1
  • A. Fekkar
    • 1
  • D. Mazier
    • 1
    • 2
    • 3
  • L. Paris
    • 1
    Email author
  1. 1.AP-HP, Laboratoire de Parasitologie-MycologieGroupe Hospitalier Pitié-SalpétrièreParisFrance
  2. 2.Université Pierre et Marie Curie-Paris 6ParisFrance
  3. 3.INSERMParisFrance

Personalised recommendations